Shanghai, China, August 22, 2024 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord Healthcare Inc. (an affiliate of Intas Pharmaceuticals, Ltd.), has received marketing approval (Notice of Compliance) from the Health Canada for HLX02 (trade name: HANQUYOU in China, HERCESSI™ in U.S., Zercepac^®in Europe

Hong Kong, August 21, 2024 --Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK; together with its subsidiaries collectively referred to as the “Group”), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approached, including energy-based devices, injectabl

With the aim of achieving localized pharmaceutical manufacturing and supply in Africa as well as enhancing the accessibility and affordability of pharmaceutical and healthcare products in the African region, Fosun Pharma is implementing a "three-step" strategic plan involving building infrastructure, improving production lines, and expanding

·HANQUYOU is the China-developed monoclonal antibody(mAb) biosimilar approved in China, the EU and the U.S.·HANQUYOU has been approved in 47 countries and regions with 5,500,000+ units shipped.·Henlius is actively collaborating with global partners to bring its therapeutics to patients worldwide and has licensed HANQUYOU out to ~100 countries and

"In the future, Fosun will continue to firmly advance its globalization strategy, transforming its globalization capability into sustained profit growth." Guo Guangchang, Chairman of Fosun International, said at the 2024 Fosun Semi-Annual Working Meeting on 20 July 2024. "Fosun's globalization is not a strategy which commences today, but has been going on

Fosun Tourism Group (the “Company”, together with its subsidiaries, the “Group”) wishes to inform shareholders (the “Shareholders”) and potential investors of the Company thatbenefiting from the worldwide easing of travel restrictions and the effective implementation of the Company’s strategy, the operations of the Group’s Club Med and Others, A

On 16 July 2024, S&PGlobal held the “Seizing Opportunities to Drive a Sustainable Future - S&P Global Sustainable1 Sustainability Seminar and the Launch of Sustainability Yearbook 2024 (China Edition)” in Beijing. Fosun International Limited (HKEX stock code: 00656, “Fosun International”) was successfully included in S&P Global’s Sustainability Yearbook 2024 (Ch

(Chengdu, China) July 11, 2024, Club Med, the pioneer of premium All-inclusive holiday lifestyle brand, today announcedthe opening of Club Med Joyview Heilongtan Resort. This marks the debut of Club Med Joyview product line intosouthwest China, further expanding Club Med'spresence in Chinese market. Located in Mei Shan City, Sichuan Province, an hour

On the afternoon of 30 June 2024, the Financial Program Center of China Media Group (CMG) officially released the “China ESG (Corporate Social Responsibility) 2024 ESG Action Report” in Beijing, China. The report evaluated 972 listed companies selected from the pool of 6,471 A-share and Hong Kong listed companies to present the ESG traits and trends of Chinese ent